Risks are shared; rewards are not. Examine the structural inequities in global pathogen data sharing and evaluate the need for a binding Benefit-Sharing framework under the WHO Pan

GS2 Healthcare
Risks are shared; rewards are not. Examine the structural inequities in global pathogen data sharing and evaluate the need for a binding Benefit-Sharing framework under the WHO Pandemic Agreement.

Examine

  • 10 marks
  • 8 min
  • 150 words
  • Medium

The Hindu

Read article →

INTRODUCTION

Global pathogen sharing rests on an asymmetry: LMICs supply biological data while HICs capture value through vaccines, therapeutics, and diagnostics (VTDs). COVID-19 exposed this imbalance, with 13% of the global population securing ~50% of vaccines, underscoring the absence of equitable benefit-sharing.

STRUCTURAL INEQUITIES IN PATHOGEN DATA SHARING

  • Asymmetric value chain: LMICs provide samples and surveillance data; HIC-based firms convert them into high-value VTDs without reciprocal access guarantees.
  • Intellectual property barriers: Patents and know-how concentrate production and pricing power, limiting affordability (e.g., Ebola drug Inmazeb at ~$6,900/treatment).
  • Weak reciprocity norms: Existing frameworks (e.g., GISAID) ensure rapid data flow but do not mandate downstream access or affordability.
  • Market concentration: Advanced manufacturing capacity is clustered in a few countries, reinforcing dependency during crises.

EVALUATION OF A BINDING BENEFIT-SHARING FRAMEWORK

  • Why binding is necessary

    • Voluntary mechanisms have failed under stress: COVAX delivered ~20% of promised doses; C-TAP saw negligible uptake—solidarity erodes when supply tightens.
    • Predictability and equity: A binding Pathogen Access and Benefit-Sharing (PABS) system can guarantee time-bound allocations (e.g., 20% of VTD output) and non-exclusive licensing.
    • Feasibility: Secure, trackable data systems (e.g., GISAID, European Genome-Phenome Archive) show that compliance and traceability are operationally viable.

  • Concerns and limits

    • Innovation disincentive argument: Some HICs (e.g., EU) contend binding obligations may deter R&D investment; however, much early-stage research is publicly funded, weakening this claim.
    • Enforcement challenges: Monitoring compliance and resolving disputes across jurisdictions can be complex.

WAY FORWARD

  • Operationalise PABS with tiered triggers (normal → PHEIC → pandemic).
  • Mandate non-exclusive licensing and technology transfer.
  • Extend scope beyond pandemics to PHEICs for early equity.
  • Build regional manufacturing capacity in LMICs to complement legal guarantees.

CONCLUSION

The current regime socialises risks but privatises rewards. A binding benefit-sharing framework under the WHO Pandemic Agreement is essential to align incentives, ensure equitable access, and sustain trust in global health cooperation.